The pharmacokinetics of paliperidone versus risperidone

Psychosomatics

Volumn 51, Issue 1, 2010, Pages 80-88

  De Leon, Jose ^a,b,c   Wynn, Gary ^d,e   Sandson, Neil B ^f  

^a Eastern State Hospital   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLYCOPROTEIN P; PALIPERIDONE; PLACEBO; RISPERIDONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG EFFICACY; DRUG EXCRETION; DRUG INTERACTION; DRUG POTENCY; ENZYME INHIBITION; HUMAN; KIDNEY FAILURE; MULTICENTER STUDY; PHENOTYPE; PSYCHOSIS; RECEPTOR BINDING; REVIEW; URINARY EXCRETION;

EID: 75849125839     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.51.1.80     Document Type: Review

References (89)

1. Flockhart DA: Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 1996; 16: 101-103
2. Lasser KE, Seger DL, Yu T, et al: Adherence to black-box warnings for prescription medications in outpatients. Arch Intern Med 2006; 166:338-344
3. Megens AA, Awouters FH, Schotte A, et al: Survey on pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994; 114:9-23
4. Heykants J, Huang ML, Mannens G, et al: The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55(suppl 5):13-17
5. Huang ML, Van Peer A, Woestenborghs R, et al: Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54:257-268
6. Janssen: Risperdal (Risperidone). Package insert (revised, December 2006). Titusville, NJ, Janssen, 2006
7. de Leon J, Armstrong SC, Cozza KL: A preliminary attempt to personalize risperidone dosing using drug- drug interactions and genetics, Part I. Psychosomatics 2008; 49:258-270
8. de Leon J, Armstrong SC, Cozza KL: A preliminary attempt to personalize risperidone dosing using drug- drug interactions and genetics, Part II. Psychosomatics 2008; 49:347-361
9. Anderson CB, True JE, Ereshefsky L, et al: Risperidone dose, plasma levels, and response, in New Research Program and Abstracts, presented at Annual Meeting, American Psychiatric Association, San Francisco, CA, May 1993 (NR 217; p 113)
10. Ereshefsky L: Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57(suppl 11): 12-25
11. Bork J, Rogers T, Wedlund P, et al: A pilot study of risperidone metabolism: the role of cytochrome P450 2D6 and 3A. J Clin Psychiatry 1999; 60:469-476
12. de Leon J, Susce MT, Pan RM, et al: CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66:15-27
13. de Leon J, Susce MT, Pan RM, et al: A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40:93-102
14. de Leon J, Susce, MT, Johnson M, et al: DNA microarray technology in the clinical environment: AmpliChip CYP 450 Test for CYP2D6 and CYP2C19 genotyping. CNS Spectrums (in press)
15. Sistonen J, Sajantila A, Lao O, et al: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17:93-101
16. Xu Y, Sun Y, Yao L, et al: Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008; 19:1423-1429
17. Lim H-S, Lee H, Lee K, et al: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25:3837-3845
18. Kiyotani K, Mushiroda T, Sasa M, et al: Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99:885-999
19. Albrecht A, Morena PG, Baumann P, et al: High dose of depot risperidone in a nonresponder schizophrenic patient. J Clin Psychopharm 2004; 24:673-674
20. Guzey C, Aamo T, Spigset O: Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer (letter). J Clin Psychiatry 2000; 61:600-601
21. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
22. Chouinard G, Jones B, Remington G, et al: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1997; 17:194-201
23. Balant-Gorgia AE, Gex-Fabry M, Genet C, et al: Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of inter-individual variability factors. Ther Drug Monit 1999; 21:105-115
24. Mauri MC, Laini V, Biscati L, et al: Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 2001; 16:57-63
25. Olensen OV, Linnet K: Simplified high-performance liquid chromatography method for determination of risperidone and 9-hydroxyrisperidone in serum from patients co-medicated with other psychotropic drugs. J Chromatogr B 1997; 698:209-216
26. Gagliano A, Germanò E, Pustorino G, et al: Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 2004; 14:39-47
27. Cheng-Shannon J, McGough JJ, Pataki C, et al: Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14:372-394
28. Castberg I, Spigset O: Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit 2005; 27:103-106
29. Nesvag R, Hendset M, Refsum H, et al: Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006; 114:21-26
30. Eerdekens M, Van Hove I, Remmerie B, et al: Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004; 70:91-100
31. Bader W, Greiner C, Wittmann M, et al: Clinical and pharmacological comments are essential to supplement therapeutic drug monitoring (TDM) of schizophrenia patients treated with longacting injectable risperidone. Biol Psychiatry 2006; 59(suppl 8S):151S
32. Harvey AT, Preskorn S: Fluoxetine pharmacokinetics and effects on CYP2C19 in young and elderly volunteers. J Clin Psychopharm 2001; 21:161-166
33. Brunswick DJ, Amsterdam JD, Fawcett J, et al: Fluoxetine and norfluoxetine plasma level after discontinuation of fluoxetine therapy. J Clin Psychopharm 2001; 21:616-618
34. de Leon, J: Psychopharmacology: atypical antipsychotic dosing: the effect of co-medication with anticonvulsants. Psychiatr Serv 2004; 55:125-128
35. de Leon J, Armstrong SC, Cozza KL: The dosing of atypical antipsychotics. Psychosomatics 2005; 46:262-273
36. Citrome L: Paliperidone: quo vadis? Int J Clin Pract 2007; 61: 653-662
37. Canuso CM, Youssef EA, Bossie CA, et al: Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008; 23:209-215
38. Dlugosz H, Nasrallah HA: Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin Pharmacother 2007; 8:2307-2313
39. Dolder C, Nelson M, Deyo Z: Paliperidone for schizophrenia. Am J Health Syst Pharm 2008; 65:403-413
40. Fowler JA, Bettinger TL, Argo TR: Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther 2008; 30:231-248
41. Meltzer HY, Bobo WV, Nuamah IF, et al: Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008; 69:817-829
42. Nussbaum A, Stroup TS: Paliperidone for schizophrenia. Cochrane Database Syst Rev 2008; 16:CD006369
43. Spina E, Cavallaro R: The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin Drug Saf 2007; 6:651-662
44. Yang LP, Plosker GL: Paliperidone extended-release. CNS Drugs 2007; 21:417-425
45. Davidson M, Emsley R, Kramer M, et al: Efficacy, safety, and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93:117-130
46. Marder SR, Kramer M, Ford L, et al: Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007; 62: 1363-1370
47. Kane J, Canas F, Kramer M, et al: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebocontrolled trial. Schizophr Res 2007; 90:147-161
48. Kramer M, Simpson G, Maciulis V, et al: Paliperidone extendedrelease tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2007; 27:6-14
49. Tzimos A, Samokhvalov V, Kramer M, et al: Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008; 16:31-43
50. Vermeir M, Naessens I, Remmerie B, et al: Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008; 36:769-779
51. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors: focus on newer-generation compounds. Life Sci 2000; 68:29-39
52. Schotte A, Janssen PF, Gommeren W, et al: Risperidone compared with new and reference antipsychotic drugs: in-vitro and in-vivo receptor binding. Psychopharmacology 1996; 124:57-73
53. van Beijsterveldt LEC, Geerts RJF, Leysen JE, et al: Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperdone in the rat. Psychopharmacology 1994; 114: 53-62
54. Aravagiri M, Yuwiler A, Marder SR: Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 1998; 139:356-363
55. Boulton DW, DeVane CL, Liston HL, et al: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71:163-169
56. Wang J-S, Zhu H-J, Markowitz JS, et al: Evaluation of antipsychotic drugs as inhibitors of multidrug-resistance transporter Pglycoprotein. Psychopharmacology 2006; 187:415-423
57. Zhu H-J, Wang J-S, Markowitz JS, et al: Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacol 2007; 32:757-764
58. Wang JS, Ruan Y, Taylor RM, et al: The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004; 7:415-419
59. Doran A, Obach RS, Smith BJ, et al: The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33:165-174
60. Ejsing B, Pedersen AD, Linnet K: P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in-vitro, in knockout mice and in drug- drug interaction experiments. Hum Psychopharmacol Clin Exp 2005; 20:493-500
61. Kirschbaum KM, Henken S, Hiemke C, et al: Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 2008; 188:298-303
62. Tsai SJ, Wang YC, Younger WYY, et al: Association study of polymorphisms of the α2a-adrenoreceptor gene with schizophrenia and clozapine response. Schizophr Res 2001; 49:53-58
63. Hartfield AW, Moore NA, Clifton PG: Serotonergic and histaminergic mechanisms involved in intra-lipid drinking? Pharmacol Biochem Behav 2003; 76:251-258
64. Shayegan DK, Stahl SM: Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004; 9(10 suppl 11):6-14
65. Reynolds GP, Templeman LA, Zhang ZJ: The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug response. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:1021-1028
66. Meltzer HY, Matsubara S, Lee JC: The ratios of serotonin-2 and dopamine-2 affinities differentiate atypical and typical antipsychotics. Psychopharmacol Bull 1989; 25:390-392
67. Dunbar F, Chue P, Fu DJ, et al: Impact of the CYP2D6 metabolizer phenotype on the safety profile of paliperidone-ER. Biol Psychiatry 2007; 61(suppl):83S
68. Barnhill J, Susce MT, Diaz FJ, et al: Risperidone half-life in a patient taking paroxetine: a case report. Pharmacopsychiatry 2005; 38:223-225
69. Bergley DJ: ABC transporter and the blood- brain barrier. Curr Pharm Design 2004; 10:1295-1312
70. Loscher W, Potschka H: Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2:86-98
71. Endres CJ, Hsiao P, Chung FS, et al: The role of transporters in drug interactions. Eur J Pharm Sci 2006; 27:501-517
72. Sasongko L, Link JM, Muzi M, et al: Imaging P-glycoprotein transport activity at the human blood-barrier with positron emission tomography. Clin Pharmacol Ther 2005; 77:503-514
73. Bialer M, Doose DR, Murthy B, et al: Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43:763-780
74. de Leon J, Bork JA: Risperidone and the cytochrome P4503A (letter). J Clin Psychiatry 1997; 58:450
75. Yatham LN, Grossman F, Augustyns I, et al: Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182:141-147
76. Mula M, Monaco F: Carbamazepine-risperidone interactions in patients with epilepsy. Clin Neuropharmacol 2002; 25:97-100
77. Ono S, Mihara K, Suzuki A, et al: Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002; 162:50-54
78. Spina E, Avenoso A, Facciolà G, et al: Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of co-medication with carbamazepine or valproate. Ther Drug Monit 2000; 22: 481-485
79. Cleton A, Talluri K, Mertens A, et al: No pharmacokinetic interaction between trimethoprim and paliperidone-ER in healthy subjects. Biol Psychiatry 2006; 59(suppl 8S):41S
80. Dubuske LM: The role of P-glycoprotein and organic aniontransporting polypeptides in drug interactions. Drug Saf 2005; 28:789-801
81. Gerloff T: Impact of genetic polymorphisms in transmembrane carrier systems on drug and xenobiotic distribution. Naunyn-Schmiedeberg's Arch Pharmacol 2004; 369:69-77
82. Endres CJ, Hsiao P, Chung FS, et al: The role of transporters in drug interactions. Eur J Pharm Sci 2006; 27:501-517
83. Urakami Y, Kimura N, Okuda M, et al: Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004; 21:976-981
84. American Medical Association: Drug Evaluations Annual, 1993. Milwaukee, WI, American Medical Association, 1993
85. Wright JG, Boddy AV: All half-lives are wrong, but some halflives are useful. Clin Pharmacokinet 2001; 40:237-244
86. Schooler N, Bossie C, Canuso C, et al: A "virtual" comparison of paliperidone-ER and risperidone in patients with schizophrenia. Schizophr Bull 2007; 33:459
87. Arakawa R, Ito H, Takano A, et al: Dose-finding study of paliperidone-ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology 2008; 197:229-235
88. Kapur S, Remington G, Zipursky RB, et al: The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57:L103-107
89. Eerdekens M, Kramer M, Rossenu S, et al: Effect of paliperidone extended-release tablets on prolactin exposure in patients with stable schizophrenia. Presented at Annual Meeting, USP & MHC, New Orleans, LA, November 2006 (Abstract # 335)